Skip to main content

Table 1 Patient demographics and baseline characteristics of randomized patients.

From: Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

 

T/HCTZ (n = 428)

V/HCTZ (n = 412)

Gender (n [%])

  

   Men

230 (53.7)

239 (58.0)

   Women

198 (46.3)

173 (42.0)

Age

  

   Mean ± SD (years)

58.5 ± 9.7

59.2 ± 9.7

   ≥ 65 years (n [%])

122 (28.5)

119 (28.9)

Race (n [%])

  

   White

292 (68.2)

292 (70.9)

   Black

61 (14.3)

59 (14.3)

   Asian

75 (17.5)

61 (14.8)

BMI

  

   Mean ± SD (kg/m2)

33.6 ± 5.7

33.4 ± 5.3

Hypertension duration

  

   Mean ± SD (years)

9.2 ± 9.5

8.9 ± 9.2

24-hour ABP

  

   Mean SBP ± SD (mm Hg)

148.0 ± 11.9

147.8 ± 12.4

   Mean DBP ± SD (mm Hg)

83.1 ± 9.2

83.3 ± 10.2

Trough seated BP

  

   Mean SBP ± SD (mm Hg)

156.8 ± 12.5

157.1 ± 12.3

   Mean DBP ± SD (mm Hg)

92.1 ± 9.3

91.7 ± 9.8

HbA1c (%)

  

   Mean ± SD

7.0 ± 1.1

7.2 ± 1.2

  1. ABP: ambulatory blood pressure; DBP: diastolic blood pressure; T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ; valsartan 160 mg plus HCTZ 12.5 mg; SBP: systolic blood pressure.